

**Prontuario delle Formulazioni Galeniche per Malattie Rare**

Nome Medicinale Galenico	Conf.	Forma Farm.	Indicazione Terapeutica	Cod. Pat. Rara	Asl / Aso	Letteratura a supporto	Cod.Region. Galenico	Atc	Tariffa (€)
Acido acetilsalicilico 20 mg	30	capsule	Sindrome di Kawasaki	RG0040	ASL TO 3	Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.Hsieh KS, Weng KP, Lin CC, Huang TC, Lee CL, Huang SM. Pediatrics. 2004 Dec;114(6):e689-93.	GROCRG001	C01E	8,1
Baclofene 1 mg	30	cartine	disturbi del metabolismo e degli amminoacidi/cistinuria	RCG040	ASL TO 2 Giovanni Bosco	"Orally administered drugs in the treatment of spasticity" Campistol J.1: Rev Neurol. 2003 Jul 1-15;37(1):70-4.	GROCR002	A16A	8,4
Baclofene 300 mg	30	capsule	corea di Huntington	RF0080	ASL TO 2 Giovanni Bosco	A controlled clinical trials of baclofen as protective therapy in early Huntington's disease. Shoulson I et al. Ann Neurol. 1989 Mar;25(3):252-9. PMID: 2524992	GROCRF003	N07	
Betaina base 1200 mg	30	cartine	omocistinuria	RCG040	ASL NO	Wilcken, D. E. L.; Wilcken, B.; Dudman, N. P. B.; Tyrrell, P. A. :Homocystinuria--the effects of betaine in the treatment of patients not responsive to pyridoxine. New Eng. J. Med. 309: 448-453, 1983.	GROCR004	A16A	9
Bicarbonato di sodio 8,4%	1 L	soluzione acquosa	tubulopatia renale congenita	RJG011- codice esenzione valido solo per la Regione Piemonte	ASL BI	Manuale Merck- Anomalie congenite - anomalie nel trasporto renale	GROSRJ005	G04B	5

Prontuario delle Formulazioni Galeniche per Malattie Rare

Capsaicina 31,25 mg	100 30 /	capsule	sclerodermia (sclerosi sistemica progressiva)	RM0091 - codice esenzione valido solo per la Regione Piemonte	ASL TO 2 Giovanni Bosco	"Preliminary protocol for systemic administration of capsaicin for the treatment of the burning mouth syndrome" Lauritano D, Petruzzi M, Baldoni M., Minerva Stomatol. 2003 Jun;52(6):273-8.	GROCRM006	D11	8,50 (30 cps) / 17,8 (100cps)
Ciclosporina 0,5%	10 ml	collirio	pemfigoide benigno delle mucose	RL0030	ASL VC Vercelli	Manuale Merck - Affezioni dermatologiche-bollose	GRFSRL007	S01X	18,5
Citrullina 500 mg	30	capsule	intolleranza alle proteine con lisinuria	RCG040	ASL NO	Mizutani N, Kato T, Maehara M, Watanabe K, Ban M. "Oral administration of arginine and citrulline in the treatment of lysinuric protein intolerance."Tohoku J Exp Med.1984 Jan;142(1):15-24	GROCRC008	A12C	11,2
Clobetasolo 0,5mg in idrossietilcellulosa 4% anaparti	100 g	unguento	pemfigo orale	RL0030	AOU S. Giovanni Battista, ASL 19 AT, ASO Maggiore della Carità Novara	A Comparison of Two Regimens of Topical Corticosteroids in the Treatment of Patients with Bullous Pemphigoid: A Multicenter Randomized Study.Joly P, et al -J Invest Dermatol. 2009 Jan 29. doi:10.1038/jid.2008.412. The role of topical corticosteroids in bullous pemphigoid in the elderly.Joly P, Fontaine J, Roujeau JC. - Drugs Aging. 2005;22(7):571-6.	GRTPR009	D11	13,8

Prontuario delle Formulazioni Galeniche per Malattie Rare

Creatina 0,5 g	100	cartine, capsule	atrofia muscolare spinale, sindrome di Werdnig-Hoffman	RFG050	ASL 19 AT	"Creatine for treating muscle disorders" Kley, R.A. The Cochrane Library, 2007. "Clinical use of creatine in neuromuscular and neurometabolic disorders" Tarnopolosky MA. Subcell Biochem.2007;46:183-204.	GROCRF010	M09	19
Creatina Monoidrata 1 g	30	cartine	miopatia congenita ereditaria	RFG070	ASL TO 2 Maria Vittoria	Shefner JM, et al. A clinical trial of creatine in ALS.Neurology 2004;63:1656-61. Persky AM, Brazeau GA. Clinical pharmacology of the dietary supplement creatine monohydrate. Pharmacol Rev 2001;53:161-76. www.farmacovigilanza.org-Impiego terapeutico creatina orale.	GROCRF011	M09	8,5
Creatina 2 g – 3 g	90 30 /	cartine	distrofia muscolare (es.Distrofia muscolare di Duchenne)	RFG080	ASL TO 2 Giovanni Bosco, ASL TO 3	"Creatine May Help Muscular Dystrophy- Researchers Say the Nutritional Supplement May Improve Muscle Strength" Kley, R.A. The Cochrane Library, 2007. "Creatine monohydrate as a therapeutic aid in muscular dystrophy", Pearlman JP, Fielding RA., Nutr Rev. 2006 Feb;64(2 Pt 1):80; Clinical use of creatine in neuromuscular and neurometabolic disorders.Tarnopolsky MA. Subcell Biochem. 2007;46:183-204.	GROCRF012	M09	8,9 (3 g 30 cartine) / 10,5 (2 g 30 cartine) / 23,7(2 g 90 cartine)

Prontuario delle Formulazioni Galeniche per Malattie Rare

Creatina 2 g	30	cartine	neuropatie ereditarie	RFG060	ASL TO 3	Resistance training exercise and creatine in patients with Charcot-Marie-Tooth disease. Chetlin RD, Gutmann L, Tarnopolsky MA, Ullrich IH, Yeater RA. Muscle Nerve. 2004 Jul;30(1):69-76.	GROCRF013	N07	8,5
Creatina 2,5 g	30	cartine	SLA	RF0100	ASL TO 3	Creatine and its potential therapeutic value for targeting cellular energy impairment in neurodegenerative diseases. Adihetty PJ, Beal MF. Neuromolecular Med. 2008;10(4):275-90 Creatine monohydrate in ALS: effects on strength, fatigue, respiratory status and ALSFRS. Rosenfeld J, King RM, Jackson CE, Bedlack RS, Barohn RJ, Dick A, Phillips LH, Chapin J, Gelinis DF, Lou JS. Amyotroph Lateral Scler. 2008 Oct;9(5):266-72.	GROCRF014	N07	8,7

Prontuario delle Formulazioni Galeniche per Malattie Rare

DMSO 15% in crema base	500 g	pomata	amiloidosi	RCG130	ASL TO 2 Giovanni Bosco	"Intermittent use of topical dimethyl sulfoxide in macular and papular amyloidosis" Ozkaya-Bayazit E, Kavak A, Gungor H, Ozarmagan G, International Journal of Dermatology 1998; 37:949-954; "Multidisciplinary utilization of dimethyl sulfoxide:pharmacological, cellular, and molecular aspects" Santos NC, Figueira Coelho J, Martins-Silva J, Saldanha C, Biochemical Pharmacology 2003; 65:1035-1041; "Medical use of dimethyl sulfoxide " Swanson BN, Rev. Clin. Basic Pharm. 1985;5(1-2):1-33.	GRTPRC015	D11	22
EDTA colliro 0,05 M	20 ml	collirio	cheratite a bandelletta	RN1500	A.S.O. S. Croce e Carle	EDTA chelation for calcific band keratopathy: results and long-term follow-up.Najjar DM,et al - Am J Ophthalmol. 2004 Jun;137(6):1056-64.	GRFSRN016	S01X	5,3

Prontuario delle Formulazioni Galeniche per Malattie Rare

Fludrocortisone 0,0001 mg	100	capsule	Adrenoleucodistrofia	RF0120	ASL TO 3	Adrenal steroids in adrenomyeloneuropathy. Dehydroepiandrosterone sulfate, androstenedione and 17alpha-hydroxyprogesterone. Wichers-Rother M, Grigull A, Sokolowski P, Stoffel-Wagner B, Köhler W. J Neurol. 2005 Dec;252(12):1525-9. X-linked adrenoleukodystrophy is a frequent cause of idiopathic Addison's disease in young adult male patients. Laureti S, Casucci G, Santeusano F, Angeletti G, Aubourg P, Brunetti P. J Clin Endocrinol Metab. 1996 Feb;81(2):470-4.	GROCRF017	M09	12
Glicerolato d'amido 10% in vaselina	500 g	crema	ittiosi congenita	RNG070	ASL TO 2 Giovanni Bosco, AOU S. Giovanni Battista	Medicamenta	GRTPRN018	D11	19,4
Glicerolato d'amido 10% in vaselina filante	500 g	unguento	pitiriasi rubra pilaris	RL0081- codice esenzione valido solo per la Regione Piemonte	ASL TO 2 Maria Vittoria	How I treat...pityriasis rubra pilaris. Fraiture AL, Braham C, Pierard-Franchimont C, Pierard GE. - Rev Med Liege.2002 Jun;57(6):363-5	GRTPRL019	D11	18,9
Glicerolato d'amido 10% in dermo base grassa	500 g	crema	ittiosi congenita	RNG070	ASL TO 2 Giovanni Bosco	Medicamenta	GRTPRN052	D11	32,8

Prontuario delle Formulazioni Galeniche per Malattie Rare

Levodopa/carbidopa dosaggi vari (pro chilo)	30	cartine	difetto di tetraidrobiopterina da deficit di ptps	RCG040	A.S.O. S. Croce e Carle	Disorders of tetrahydrobiopterin metabolism and their treatment. Shintaku H. - Curr Drug Metab. 2002 Apr;3(2):123-31.	GROCR020	N07	8
Miscela di fosfati (1 ml/41 mg di P)	1 L	soluzione	tubulopatia renale congenita	RJG011- codice esenzione valido solo per la Regione Piemonte	ASL NO	Manuale Merck- Anomalie congenite - anomalie nel trasporto renale Pharmacotherapy - A pathophysiological approach 7th edition 2008 -Dipiro J T, Talbert RL	GROSRJ021	G04B	9
Miscela di fosfati aromatizzata al cacao	1 L	soluzione	rachitismo ipofosfatemico vitamina d resistente	RC0170	ASL BI	Bouillon R et al, Intestinal calcium absorption: molecular vitamin D mediated mechanism, J Cell Bioch 2003; 88: 332-9 Rowe PSN, The molecular background to hypophosphatemic rickets, Arch Dis Child 2000; 83: 192-4 Baroncelli G et al, Effect of GH treatment on final height, phosphate metabolism, and BMD in children with X-linked hypophosphatemic rickets, J Pediatr 2001; 138: 236-43 Harrison Principi di Medicina Interna, 16° edizione, volume II, pag. 1917	GROSRC022	A11CC	9,9

Prontuario delle Formulazioni Galeniche per Malattie Rare

Mometasone furoato in dermo base grassa	60 g / 120 g	crema	pemfigo	RL0060	ASL TO 2 Giovanni Bosco	A Comparison of Two Regimens of Topical Corticosteroids in the Treatment of Patients with Bullous Pemphigoid: A Multicenter Randomized Study. Joly P, et al -J Invest Dermatol. 2009 Jan 29. doi:10.1038/jid.2008.412. The role of topical corticosteroids in bullous pemphigoid in the elderly. Joly P, Fontaine J, Roujeau JC. - Drugs Aging. 2005;22(7):571-6.	GRTPL028	D11	15,4 (60g) / 24,4 (120g)
Nifedipina AR 20mg	100	capsule	iperaldosteronismo primitivo (con ipertensione)	RCG010	ASL TO 2 Maria Vittoria	Scheda Tecnica di Adalat AR 20 mg cp.	GROCR054	C03DA	8
Oxitriptano dosaggi vari (pro chilo)	30	cartine	difetto di tetraidrobiopterina da deficit di ptps	RCG040	A.S.O. S. Croce e Carle	Disorders of tetrahydrobiopterin metabolism and their treatment. Shintaku H. - Curr Drug Metab. 2002 Apr;3(2):123-31.	GROCR023	N07	10,5
Piridostigmina bromuro 34 mg	30	capsule	miastenia gravis	RFG171-codice esenzione valido solo per la Regione Piemonte	ASL TO 2 Maria Vittoria	Diagnostic and treatment of myasthenia gravis in children. Krocicka S, Steczkowska M, Nowak A, Kacinski M. - Przegl Lek. 2008;65(11):783-8. Myasthenia gravis. Fleury MC, Tranchant C. Rev Prat. 2008 Dec 31;58(20):2217-24.	GROCRF024	M09	9,8



Prontuario delle Formulazioni Galeniche per Malattie Rare

Potassio Canrenoato 6,25 mg	30	capsule	iperaldosteronismo primitivo	RCG010	ASL TO 2 Maria Vittoria	Primari hyperaldosteronism: from diagnosis to treatment. Wemeau JL, Mounier-Vehier C, Carnaille B, Douillard C. - Press Med. 2009 Apr;38(4):633-42. Epub 2009 Mar 18. Idiopathic primary hyperaldosteronism: normalization of plasma aldosterone-receptor antagonist potassium canrenoate. Armanini D, Scaroni C, Mattarello MJ, Fiore C, Albiger N, Sartorato P J Endocrinol Invest. 2005 Mar;28(3):236-40.	GROCR025	C03DA	8,6
Potassio citrato 3g – 5g	30	cartine	Cistinuria	RCG040	ASL TO 3	Renal stone disease: Causes, evaluation and medical treatment. Heilberg IP, Schor N. Arq Bras Endocrinol Metabol. 2006 Aug;50(4):823-31.	GROCR026	C03D	8,6 (3g) / 9,1 (5 g)
Propranololo 3-7-9-15 mg	30	capsule	gravi anomalie congenite senza ritardo mentale	RNG111 - codice esenzione valido solo per la Regione Piemonte	ASL TO 2 Giovanni Bosco, ASL TO 4, ASO Maggiore della Carità Novara	Manuale Merck - Pediatria - Anomalie congenite	GROCRN027	C	8,7

Prontuario delle Formulazioni Galeniche per Malattie Rare

Quercetina 175 mg/bromelina 60 mg/papaina 60 mg	100	capsule	cistite interstiziale	RJ0030	ASL VC Vercelli, ASL CN 1 Mondovì, ASL NO, ASL TO 4	"Treatment of Interstitial Cystitis with a Quercetin Supplement (Cysta-Q)" Katske F, Shoskes DA, Sender M, Poliakin R, Gagliano K, Rajfer J. Techniques in Urology 7(1):44-46, March 2001	GROCRJ053	G04B	23
Quercetina 175 mg/condroitina solfato 60 mg/glucosamina solfato 60 mg	100	capsule	cistite interstiziale	RJ0030	ASL VC Vercelli	Treatment of refractory interstitial cystitis/painful bladder syndrome with CystoProtek--an oral multi-agent natural supplement. Theoharides T C et al. Can. J. Urol.2008 Dec;15(6):4410-4	GROCRJ029	G04B	21,5
Quercetina 100 mg/condroitina solfato 125 mg/glucosamina solfato 125 mg/rutina 12,5 mg/sodio ialuronato 7,25 mg	100	capsule	cistite interstiziale	RJ0030	ASL NO	Treatment of refractory interstitial cystitis/painful bladder syndrome with CystoProtek--an oral multi-agent natural supplement. Theoharides T C et al. Can. J. Urol.2008 Dec;15(6):4410-4	GROCRJ030	G04B	27

Prontuario delle Formulazioni Galeniche per Malattie Rare

Riboflavina 50 mg	100	30 / capsule/cartine	sindrome di Melas	RN0170	ASL NO, ASL TO 2 Giovanni Bosco	MELAS di Salvatore DiMauro, MD, attraverso GENEReviews <a href="http://www.genetests.org">www.genetests.org</a> MELAS Syndrome di Fernando Scaglia, MD articolo di eMedicine <a href="http://www.emedicine.com/pe&lt;br/&gt;d/topic1406.htm">http://www.emedicine.com/pe d/topic1406.htm</a> MELAS Syndrome di Mary Kugler MSN, RN, Bc <a href="http://rarediseases.about.com&lt;br/&gt;/cs/melassynndrome/a/021204.&lt;br/&gt;htm">http://rarediseases.about.com /cs/melassynndrome/a/021204. htm</a> Strokes e Transient Events in Mitochondrial cytopathies di Bruce cohen, MD Articolo in Pensa ai mitocondri, compendium, disponibile attraverso UMDF "MELAS syndrome with mitochondrial tRNA(Leu)(UUR) mutation: correlation of clinical state, nerve conduction, and muscle 31P magnetic resonance spectroscopy during treatment with nicotinamide and riboflavin." Penn AM, Lee JW, Thuillier P, Wagner M, Maclure KM, Menard MR, Hall LD, Kennaway NG., Neurology. 1992 Nov;42(11):2147-52. "Long-term treatment with ideb	GROCRN031	N07	8,7 (30 cps) / 18,2 (100cps)
-------------------	-----	-------------------------	-------------------	--------	--	---	-----------	-----	---------------------------------

Prontuario delle Formulazioni Galeniche per Malattie Rare

Riboflavina 50 mg – 60mg	30	cachets	neuropatia ottica ereditaria	RF0300	ASL TO 2 Maria Vittoria	Neurochemistry International 40 (2002) 573–584 Optic nerve degeneration and mitochondrial dysfunction:genetic and acquired optic neuropathies Valerio Carelli □, Fred N. Ross-Cisneros, Alfredo A. Sadun Doheny Eye Institute, USC Keck School of Medicine, DVRC 311, 1355 San Pablo Street, Los Angeles, CA 90033, USA Accepted 30 October 2001	GROCRF032	N07	8,1
Riboflavina 50 mg	30	capsule	Malattia di Leigh	RF0030	ASL TO 3	[Leigh syndrome and leukodystrophy due to partial succinate dehydrogenase deficiency: regression with riboflavin]Pinard JM, Marsac C, Barkaoui E, Desguerre I, Birch-Machin M, Reinert P, Ponsot G.Arch Pediatr. 1999 Apr;6(4):421-6.	GROCRF033	N07	8,2

Prontuario delle Formulazioni Galeniche per Malattie Rare

Riboflavina 100 mg	30	capsule	alterazioni congenite del metabolismo delle lipoproteine	RCG070	ASL TO 3	Riboflavin-Responsive Metabolic Myopathy with Abnormal Fatty Acid Oxidation and Defective Intramitochondrial Respiratory Complexes. Lodovica Vergani, Flavio Collatuzzo, Giuliana Schievano and Corrado Angelini. BAM 6 (2): 135-138,1996. Riboflavin-Theraphy. Biochemical heterogeneity in two adult lipid storage myopathies. Lodovica Vergani, Maria Barile, Corrado Angelici, Alberto B. Burlina, Leo Nijtmans, Maria Pia Freda, Carmen Brizio, Elisabetta Zerbetto and Federica Dabbeni-Sala. Brain (1999), 122, 2401-2411.	GROCR034	C10A	8,5
Salbutamolo 2 mg	30	capsule	Atrofie muscolari spinali	RFG050	ASL NO	Daily salbutamol in young patients with SMA type II, Neuromuscul Disord.2008 Jul;18(7):536-40. Epub 2008 Jun 24	GROCRF035	M09	8
Sildenafil 2,5 mg	30	cartine	mucopolidiosi tipo II	RCG090	ASL BI	The use of Sildenafil in Persistent Pulmonary Hypertension of the Newborn Vargas-Origel et Al.-Am J Perinatal 2009 Oct.28 Sildenafil for the Tratment of Pulmonary Hypertension in pediatric Patients-Huddleston et Al.-Pediatric Cardiology Vol.30 (2009)	GROCR036	C10A	25

**Prontuario delle Formulazioni Galeniche per Malattie Rare**

Sodio cloruro 250 mg	30	cartine	tubulopatia renale congenita	RJG011- codice esenzione valido solo per la Regione Piemonte	ASL NO	Harrison Principi di Medicina Interna, 16° edizione, volume II, pag. 1917	GROCRJ037	G04B	7,9
Soluzione di joulie	500 ml	soluzione	rachitismo ipofosfatemico vitamina d resistente da sindrome Fanconi-Bickel	RC0170	ASL 19 AT, ASO Maggiore della Carità Novara	Norme di buona preparazione galenica 200;201 M. Corsi, G. Masoni; L. Manechia; C. Cassano	GROSRC038	A11CC	9,1
Tiamina 150 mg	30	capsule	Malattia di Leigh	RF0030	ASL TO 3	Outcome of thiamine treatment in a child with Leigh disease due to thiamine-responsive pyruvate dehydrogenase deficiency. Di Rocco M, Lamba LD, Minniti G, Caruso U, Naito E. Eur J Paediatr Neurol. 2000;4(3):115-7. Pyruvate dehydrogenase deficiency in a child responsive to thiamine treatment. Pastoris O, Savasta S, Foppa P, Catapano M, Dossena M. Acta Paediatr. 1996 May;85(5):625-8.	GROCRF039	N07	8,2

Prontuario delle Formulazioni Galeniche per Malattie Rare

Ubidecanrenone 250-300 mg	100	30 /	capsule	sindrome di Melas	RN0710	ASL TO 2 Giovanni Bosco	"Coenzima Q e malattie mitocondriali: dalla biochimica alle implicazioni terapeutiche" Toscano A, Musumeci O, Neurol Sci 2004;25:S317-319; "Muscle coenzyme Q10 concentrations in patients with probable and definite diagnosis of respiratory chain disorders" Montero R, Artuch R, Briones P, Nascimento A et al Biofactors, 2005; 25(1-4):109-15; "Cerebellar ataxia with coenzyme Q10 deficiency : diagnosis and follow-up after coenzyme Q10 supplementation" Artuch R, Brea- Calvo G, Briones P, Aracil A et al. J Neurol Sci 2006;246 (1-2):153-8.	GROCRN040	N07	16,2 (250mg 30 cps) / 42 (250 mg100cps) / 17 (300 mg 30 cps) / 46,3 (300mg 100cps)
Ubidecarenone 300 mg		30	capsule	SLA	RF0100	ASO Maggiore della Carità Novara, ASL TO 3	"A two-stage design for a phase II clinical trial of coenzyme Q10 in ALS" Levy G, Neurology. 2006 Mar 14;66(5):660-3 "Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS" Ferrante KL; Neurology 2005 Dec 13;65(11):1834-6 "Neuroprotective agents for clinical trials in ALS: a systematic assessment" Traynor BJ. Neurology. 2006 Jul 11;67(1):20-7	GROCRF041	N07	17

Prontuario delle Formulazioni Galeniche per Malattie Rare

Ubidecarenone 1000mg (alto dosaggio)	30	cachets	SLA	RF0100	ASL TO 2 Maria Vittoria	"Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS" Ferrante KL; Neurology 2005 Dec 13;65(11):1834-6	GROCRF042	N07	86,6
Ubidecarenone 300 mg	30 / 100	capsule	corea di Huntington	RF0080	ASL TO 2 Giovanni Bosco	"Coenzyme Q10: a review of its promise as a neuroprotectant" Young AJ, Johnson S, Steffens DC, Doraiswamy PM., CNS Spectr. 2007 Jan;12(1):62-8. "Coenzyme Q10 administration and its potential for treatment of neurodegenerative diseases.", Beal MF., 1: Biofactors. 1999;9(2-4):261-6.	GROCRF043	N07	17 (30 cps) / 46,3 (100cps)



Prontuario delle Formulazioni Galeniche per Malattie Rare

<p>Ubidecarenone 300 mg / 600 mg</p>	<p>50 30 /</p>	<p>cachets</p>	<p>miopatia mitocondriale</p>	<p>RN0710</p>	<p>A.S.O. S. Croce e Carle</p>	<p>"Coenzima Q e malattie mitocondriali: dalla biochimica alle implicazioni terapeutiche" Toscano A, Musumeci O, Neurol Sci 2004;25:S317-319;                  "Muscle coenzyme Q10 concentrations in patients with probable and definite diagnosis of respiratory chain disorders" Montero R, Artuch R, Briones P, Nascimento A et al Biofactors, 2005; 25(1-4):109-15;                  "Cerebellar ataxia with coenzyme Q10 deficiency : diagnosis and follow-up after coenzyme Q10 supplementation" Artuch R, Brea- Calvo G, Briones P, Aracil A et al. J Neurol Sci 2006;246 (1-2):153-8.</p>	<p>GROCRN044</p>	<p>N07</p>	<p>35,2 (300mg) / 102 (600mg 50 cachets) / 63 (600mg 30 cachets)</p>
<p>Urea 10%,ac.lattico 5% in crema base magra</p>	<p>500 g</p>	<p>crema</p>	<p>ittiosi congenita</p>	<p>RNG070</p>	<p>ASL TO 2 Maria Vittoria, ASL TO 3</p>	<p>Improved topical treatment of lamellar ichthyosis: a double-blind study of four different cream formulations.- Ganemo A,Virtanen M,Vahlquist A. - Br J Dermatol. 1999 Dec;141(6):1027-32.                  Ichthyosis: clinical manifestations and practical treatment options. Oji V, Traupe H.Am J Clin Dermatol. 2009;10(6):351-64.</p>	<p>GRTPRN045</p>	<p>D11</p>	<p>22,3</p>

Prontuario delle Formulazioni Galeniche per Malattie Rare

Urea 10% Glicerolo 5% Crema base	500 g	crema	Ittiosi congenita	RNG070	ASL TO 2 Maria Vittoria, ASL TO 2 Giovanni Bosco, ASL TO 3	Improved topical treatment of lamellar ichthyosis: a double-blind study of four different cream formulations.- Ganemo A,Virtanen M,Vahlquist A. - Br J Dermatol. 1999 Dec;141(6):1027-32. Ichthyosis: clinical manifestations and practical treatment options. Oji V, Traupe H.Am J Clin Dermatol. 2009;10(6):351-64.	GRTPRN046	D11	19
Urea 5% Glicerolo 5% Crema base	500 g	crema	Ittiosi congenita	RNG070	ASL TO 2 Maria Vittoria	Improved topical treatment of lamellar ichthyosis: a double-blind study of four different cream formulations.- Ganemo A,Virtanen M,Vahlquist A. - Br J Dermatol. 1999 Dec;141(6):1027-32. Ichthyosis: clinical manifestations and practical treatment options. Oji V, Traupe H.Am J Clin Dermatol. 2009;10(6):351-64.	GRTPRN047	D11	17,7
Urea 5% Glicerolo 5% Crema base q.b. 1 kg	1000 g	crema	Lichen Sclerosus et Atrophicus	RL0060	ASL TO 3	Lichen Sclerosus et Atrophicus, bullous morphea, and systemic lupus erythematosus: a case report. Kuan-Hsun Wu, Yang-Shia Dai, Ming-Jer Tsai, Shih-Chiang Lin, Ling-Hua Wang, Miao-Tsu Huang, Bor-Luen Chiang. J Microbiol Immunol Infect. 2000;33:53-56.	GRTPRL055	D11	34,8

Prontuario delle Formulazioni Galeniche per Malattie Rare

Urea 30% in crema base magra	500 g	crema	cheratodermia palmo-plantare (ipercheratosi epidermica)	RN0600	ASL TO 2 Maria Vittoria	Hereditary Palmoplantar Keratodermas. Braun-Falco M. - J Dtsch Dermatol Ges. 2009 Apr1.[Epub ahead of print]. Water content of the skin following salicylic acid and urea treatment. - Racz I, Soos G, Jakab E. - Hautarzt. 1989;40 Suppl 9:61-2.	GRTPRN048	D11	18
Urea 5% in vaselina bianca	500 g	crema	sclerodermia (sclerosi sistemica progressiva)	RM0091- codice esenzione valido solo per la Regione Piemonte	ASL TO 3, AOU S. Giovanni Battista	Lichen Sclerosus et Atrophicus, bullous morphea, and systemic lupus erythematosus: a case report. Kuan-Hsun Wu, Yang-Shia Dai, Ming-Jer Tsai, Shih-Chiang Lin, Ling-Hua Wang, Miao-Tsu Huang, Bor-Luen Chiang. J Microbiol Immunol Infect. 2000;33:53-56.	GRTPRM049	D11	15,2
Vaselina salicilica unguento 10%	500 g	crema	Ittiosi congenita	RNG070	ASL TO 3	Ichthyoses - Part 1: Differential diagnosis of vulgar ichthyoses and therapeutic options. Krug M, Oji V, Traupe H, Berneburg M. J Dtsch Dermatol Ges. 2009 Jun;7(6):511-9.	GRTPRN050	D11	16,5

Prontuario delle Formulazioni Galeniche per Malattie Rare

Vaselina salicilata 20%	500 g	unguento	cheratodermia palmo-plantare (ipercheratosi epidermica)	RN0600	ASL TO 2 Maria Vittoria	Hereditary Palmoplantar Keratodermas. Braun-Falco M. - J Dtsch Dermatol Ges. 2009 Apr1.[Epub ahead of print]. Water content of the skin following salicylic acid and urea treatment. - Racz I, Soos G, Jakab E. - Hautarzt. 1989;40 Suppl 9:61-2.	GRTPRN051	D11	18,5
-------------------------	-------	----------	---	--------	-------------------------------	--	-----------	-----	------